A Phase 2 Study of Accelerated Elotuzumab Infusion, over Less than 1 Hour, in Combination with Lenalidomide and Dexamethasone, in Patients with Multiple Myeloma

Abstract

Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-hour infusion), combined with lenalidomide and dexamethasone, demonstrated durable efficacy and acceptable safety; 10% (33/321) of patients had infusion reactions (IRs; Grade 1/2: 29; Grade 3: 4). This phase 2 study (NCT02159365) investigated an accelerated infusion schedule in 70 patients with newly diagnosed multiple myeloma or RRMM. The primary endpoint was cumulative incidence of Grade 3/4 IRs by completion of treatment Cycle 2. Dosing comprised elotuzumab 10 mg/kg intravenously (weekly, Cycles 1-2; biweekly, Cycles 3+), lenalidomide 25 mg (daily, Days 1-21) and dexamethasone (28 mg orally and 8 mg intravenously, weekly, Cycles 1-2; 40 mg orally, weekly, Cycles 3+), in 28-day cycles. Premedication with diphenhydramine, acetaminophen, and ranitidine (or their equivalents) was given as in previous studies. If no IRs occurred, infusion rate was increased in Cycle 1 from 0.5 to 2 mL/min during dose 1 (∼2 hours 50 min duration) to 5 mL/min for the entire infusion by dose 3 and also during all subsequent infusions (∼1-hour duration). Median number of treatment cycles was six. No Grade 3/4 IRs occurred; only one Grade 1 and one Grade 2 IR occurred, both during the first infusion. These data support the safety of a faster infusion of elotuzumab administered over ∼1 hour by the third dose, providing a more convenient alternative dosing option for patients. This article is protected by copyright. All rights reserved.

Make an Appointment

Related Articles

[dgbm_blog_module posts_number=”3″ show_thumbnail=”off” show_author=”off” show_pagination=”off” show_more=”on” space_between=”42px” equal_height=”on” container_margin=”||||false|false” container_padding=”||||false|false” article_margin=”||||false|false” article_padding=”||||false|false” content_margin=”||||false|false” content_padding=”30px|30px|30px|30px|true|true” meta_bottom_padding=”||||false|false” button_wrapper_margin=”20px||||false|false” category_location=”top” date_margin=”10px||10px||true|false” module_class=”zdm-blog-grid” _builder_version=”4.21.0″ _module_preset=”default” title_text_color=”#17374E” title_line_height=”1.1em” read_more_font=”||||||||” read_more_text_color=”#009ACA” read_more_font_size=”16px” date_font=”|600|||||||” date_text_color=”#2C6893″ date_font_size=”13px” category_font=”|600||on|||||” category_text_color=”#2C6893″ category_font_size=”13px” category_letter_spacing=”1px” background_color=”#FFFFFF” border_width_all_post_item=”2px” border_color_all_post_item=”gcid-f0845e9b-066a-4b8b-a6b5-20f5259bbdfd” border_style_all_post_item=”dashed” global_colors_info=”{%22gcid-f0845e9b-066a-4b8b-a6b5-20f5259bbdfd%22:%91%22border_color_all_post_item%22%93}” read_more_text_color__hover_enabled=”on|desktop” read_more_text_color__hover=”#16B591″ title_text_color__hover_enabled=”on|desktop” title_text_color__hover=”#2C6893″ category_text_color__hover_enabled=”on|desktop” category_text_color__hover=”#2C6893″][/dgbm_blog_module]